Literature DB >> 24723680

One siRNA pool targeting the λ constant region stops λ light-chain production and causes terminal endoplasmic reticulum stress.

Ping Zhou1, Xun Ma1, Lakshmanan Iyer2, Chakra Chaulagain1, Raymond L Comenzo3.   

Abstract

In systemic light-chain amyloidosis, λ light chains produced by clonal plasma cells cause organ damage and early death. In pursuit of novel therapy, we developed 1 pool of short interfering RNA (siRNA) targeting the constant region of λ light chains that substantially and promptly reduces λ-light-chain production and secretion by human plasma cells regardless of sequence diversity. In clones producing intact immunoglobulin G (IgG) λ antibodies (containing paired heavy and light chains), the secretion of intact antibodies is reduced, and all 3 branches of the unfolded protein response are activated by accumulation of unpaired IgG heavy chains in the endoplasmic reticulum (ER). Moreover, an ER stress response can then become terminal with effector caspase activity mediated in part by the transcription of the Bcl-2 homology 3 domain only family member NOXA. This pool of siRNA can be used to reduce pathological λ-light-chain production and cause apoptosis in human plasma cells making intact IgGλ antibodies.
© 2014 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24723680     DOI: 10.1182/blood-2013-10-535187

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  In vitro co-expression of human amyloidogenic immunoglobulin light and heavy chain proteins: a relevant cell-based model of AL amyloidosis.

Authors:  Elena S Klimtchuk; Tatiana B Prokaeva; Brian H Spencer; Olga Gursky; Lawreen H Connors
Journal:  Amyloid       Date:  2017-06-20       Impact factor: 7.141

2.  Comprehensive molecular characterization of a heavy chain deposition disease case.

Authors:  Sébastien Bender; Maria Victoria Ayala; Vincent Javaugue; Amélie Bonaud; Michel Cogné; Guy Touchard; Arnaud Jaccard; Frank Bridoux; Christophe Sirac
Journal:  Haematologica       Date:  2018-07-19       Impact factor: 9.941

Review 3.  AL amyloidosis: from molecular mechanisms to targeted therapies.

Authors:  Giampaolo Merlini
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

Review 4.  Targeting protein aggregation for the treatment of degenerative diseases.

Authors:  Yvonne S Eisele; Cecilia Monteiro; Colleen Fearns; Sandra E Encalada; R Luke Wiseman; Evan T Powers; Jeffery W Kelly
Journal:  Nat Rev Drug Discov       Date:  2015-09-04       Impact factor: 84.694

Review 5.  Animal models of monoclonal immunoglobulin-related renal diseases.

Authors:  Christophe Sirac; Guillermo A Herrera; Paul W Sanders; Vecihi Batuman; Sebastien Bender; Maria V Ayala; Vincent Javaugue; Jiamin Teng; Elba A Turbat-Herrera; Michel Cogné; Guy Touchard; Nelson Leung; Frank Bridoux
Journal:  Nat Rev Nephrol       Date:  2018-02-19       Impact factor: 28.314

6.  siRNA targeting the κ light chain constant region: preclinical testing of an approach to nonfibrillar and fibrillar light chain deposition diseases.

Authors:  X Ma; P Zhou; S W Wong; M Warner; C Chaulagain; R L Comenzo
Journal:  Gene Ther       Date:  2016-06-20       Impact factor: 5.250

Review 7.  Targeting Proteotoxic Stress in Cancer: A Review of the Role that Protein Quality Control Pathways Play in Oncogenesis.

Authors:  Matthew Ho Zhi Guang; Emma L Kavanagh; Luke Paul Dunne; Paul Dowling; Li Zhang; Sinéad Lindsay; Despina Bazou; Chia Yin Goh; Cathal Hanley; Giada Bianchi; Kenneth C Anderson; Peter O'Gorman; Amanda McCann
Journal:  Cancers (Basel)       Date:  2019-01-09       Impact factor: 6.639

Review 8.  Future Perspectives.

Authors:  Angela Dispenzieri; Giampaolo Merlini
Journal:  Hematol Oncol Clin North Am       Date:  2020-12       Impact factor: 3.722

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.